



## General description

---

INN	Pembrolizumab
Medicine type	Biological agent
EML status history	First added in 2019 (TRS 1021) for <b>Melanoma of skin</b> Application rejected in 2019 (TRS 1021) for <b>Other specified malignant neoplasms of bronchus or lung</b>
Therapeutic equivalent for	nivolumab for Melanoma of skin
Wikipedia	<a href="#">Pembrolizumab</a> 
DrugBank	<a href="#">Pembrolizumab</a> 

## Recommendations

---

Section Immunomodulators

Parenteral > General injections > IV: 50 mg powder for injection

### Indications

Other specified malignant neoplasms of bronchus or lung

